Aakash Desai, Associate Director, Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared on LinkedIn:
WCLC26 in Seoul is just 13 days away. Excited for the data, but let me put the studies in clinical perspective:
SCLC
- TAISHAN-302 and ARTEMIS-008 are B7-H3 ADCs versus topotecan.
Tarlatamab is already the SOC preferred after platinum based chemotherapy. Beating topotecan is not beating that box but will provide other options in future.
- MAVERICK (MRI ± PCI) is the one talk that can actually delete a recommendation and a trial that can turn ‘consider PCI’ into ‘MRI only’ much consistent with most of our current practice.
NSCLC (Non-Oncogenic)
- EVOKE-03 (sacituzumab plus pembrolizumab, PD-L1 ≥50% first-line) already stopped. PD-L1-high first-line stays pembrolizumab, atezolizumab, or cemiplimab ± chemo.
NSCLC (Oncogenic)
- DESTINY-Lung04 is T-DXd versus chemo-IO in first-line HER2-mutant NSCLC, not versus zongertinib.
Subsequent preferred is already T-DXd, zongertinib, or sevabertinib. After this, the 1L and 2L becomes a sequencing/preference question?
- PAPILLON OS keeps amivantamab plus chemo as preferred first line for EGFR exon 20 insertion, practice confirming
- REZILIENT3 is zipalertinib plus chemo versus chemo. Same design problem as sunvozertinib versus chemo.
- ARROS-1 TKI-naïve is the first-line audition for zidesamtinib. FDA is 2L after a ROS1 TKI, based on these results we may have another 1L option? outside of entrectinib, repotrectinib, or taletrectinib.
See the key takeaways below.”
You can also read: Adjuvant Crizotinib Fails in Resected ALK-Positive NSCLC: What E4512 Tells Us About Targeted Therapy in Early Disease